The progress of small-molecules and degraders against BCR-ABL for the treatment of CML
Y Pan, S Zeng, R Hao, M Liang, Z Shen… - European Journal of …, 2022 - Elsevier
Chronic myeloid leukemia (CML) is a malignant disease of the hematopoietic system with
crucial pathogenic protein named BCR-ABL, which endangers the life of patients severely …
crucial pathogenic protein named BCR-ABL, which endangers the life of patients severely …
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
YL Pan, SX Zeng, RR Hao, MH Liang… - European Journal of …, 2022 - europepmc.org
Chronic myeloid leukemia (CML) is a malignant disease of the hematopoietic system with
crucial pathogenic protein named BCR-ABL, which endangers the life of patients severely …
crucial pathogenic protein named BCR-ABL, which endangers the life of patients severely …
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML
YL Pan, SX Zeng, RR Hao… - European journal …, 2022 - pubmed.ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) is a malignant disease of the hematopoietic system with
crucial pathogenic protein named BCR-ABL, which endangers the life of patients severely …
crucial pathogenic protein named BCR-ABL, which endangers the life of patients severely …